Review Article A SYSTEMATIC REVIEW: EXPLORATION OF PROCESS ANALYTICAL TECHNOLOGY TECHNIQUES (PAT) AND THEIR MULTIFACETED ADVANTAGES IN INDUSTRIAL PROCESSES RAAGUL SEENIVASAN , JEY KUMAR PACHIYAPPAN , MURTHANNAGARI VIVEK REDDY , GNK GANESH * Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, Nilgiris. Tamilnadu. India * Corresponding author: Gnk Ganesh; * Email: gnk@jssuni.edu.in Received: 01 Nov 2023, Revised and Accepted: 20 Dec 2023 ABSTRACT FDA initiated the PAT technology framework in the year of 2004 with the guidelines of “A framework of innovative pharmaceutical development, manufacturing and quality assurance. With that, the International Council for Harmonisation has also initiated continuous process verification to overcome the limitations of traditional methods and improve the understanding of the process and quality of the product throughout the product lifecycle. Since the year of implementation, the advancement of analytical and chemometric tools has evolved to deliver consistent quality products by understanding their process and product performance. However, the pharmaceutical industry was lacking in this technicality and implementation of highly regulated specifications. To this respect, we have stated some of the PAT tools, including NIR, Raman and Terahertz spectroscopy, as they will transfer to the futuristic prospects of analyzing the drug product with non-destructive, improved process understanding, real-time monitoring, and enhanced data integrity. This review article emphasizes the importance of PAT technology with different monitoring processes with their historical background and regulatory framework. Special attention was given to strategies, challenges, opportunities, and the compatibility of PAT tools with data fusion. Further, this will give a high-priority disciplinary scientific topic to Pharma 4.0. Keywords: PAT tools, NIR spectroscopy, Raman spectroscopy, Non-destructive, Real-time monitoring, Dissolution © 2024 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (https://creativecommons.org/licenses/by/4.0/) DOI: https://dx.doi.org/10.22159/ijap.2024v16i2.49772 Journal homepage: https://innovareacademics.in/journals/index.php/ijap INTRODUCTION In the Pharmaceutical industry, quality control was mainly based on end-product testing, a traditional approach based on a statistical process control approach [1]. The statistical method may include control charts, run charts, histograms, process capability analysis, or any other mathematical or statistical approaches; these are offline approaches, i.e., they focus only on the output of the process. All the offline processes are conducted to check the quality of the finished product. The main disadvantage of these traditional methods is that they mainly emphasize only the end product, and the root cause of the problem is unidentified or unclear [2-4]. Another drawback of this method is that it is very difficult to understand the process and solve the problems that arise during product manufacturing. The ICH (International Council for Harmonisation) initiated Continuous Process Verification (CVP) to overcome the limitations of traditional methods and improve the understanding of the process and quality of the product throughout the product lifecycle. It is the alternative technique for Statistical process control, which is an older approach. It enables to reduce the defects in the manufacturing process by continuous monitoring of the process. This gives a higher assurance of product quality [5]. In contrast, this approach is based upon scientific behavior and risk- based assessment to give a good quality finished product. In 2009, ICH laid down guideline Q8 (R2), which is a QbD approach that begins with a predefined objective. The main objective of this approach is a better understanding of the materials and the process parameters. It consists of six fundamental components that must be considered before the implementation of this approach. The framework consists of the following elements: defining the goal prior, identification of CQA (Critical Quality Attributes), Assessment of Risk, Design Space Development, Control Strategy, and Life Cycle Management [6-9]. Define the goal prior: It is the initial stage for the implementation of the QbD approach. Setting the goal before meeting the Target Specification is known as a Quality Target Product Profile (QTPP). It serves as a guideline for the development of quality products throughout the development stage and for the establishment of CQAs. Identification of CQAs: Evaluation of Quality Target Product Profile leads to the CQA development. It is directly proportional to the quality of the product. It is used in the risk assessment step to check the root cause of the problem that arises during the product developmental stage. Assessment of Risk: It enables us to understand the factors that affect the quality of the product through root cause analysis. The factor may be CQA’S or any other process parameters. Design Space Development: It helps us to understand the combination and interaction effects of the parameters involved in the process. Identification of these enables an optimized process. Control Strategy: It is the ideas and information that is obtained from the previous manufacturing process, Literature survey, or any other process parameters. Life Cycle Management: It ensures that the product is maintained at good quality all the time by providing good manufacturing practices that ensure the product's quality throughout the life cycle. This may contain the following: Validation, Real-time monitoring, Six Sigma Approach, Training, etc [10]. In September 2004, the USFDA proposed “Guidance for Industry PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance,” which is mainly focused on continuous process improvement and better understanding of the process. It also encourages the implementation of the Process Analytical Technique (PAT), which is an innovative approach. These guidelines are also the European Medical Agency and MHLW. Employing an analytical process with the PAT approach facilitates Real-time release testing (RTRT). There is an increasing use of PAT technologies, which are driven by innovative technologies that enable the improvement of the quality of the product. FDA consistently motivates the manufacturer to obey the Good Manufacturing Process, which QbD can implement, and PAT approaches. Understanding the process is made easy by using certain analytical tools, sensors, probes, and lasers that are placed in an appropriate position to provide a real-time monitoring facility. The data set obtained from those tools can be interpreted, and the real-time monitoring process is enhanced. These tools provide automation and optimization of the entire process, thus reducing the off-line testing of the products and thus reducing the time for analysis and fewer human errors [11-13]. In this review article, we have discussed the Guidelines released by the regulatory body USFDA that emphasize the implementation of the manufacturing process by means of any innovative real-time monitoring process that may include the PAT approach. We have also discussed the different monitoring processes, different PAT tools, and the analytical methods that are employed in the International Journal of Applied Pharmaceutics ISSN- 0975-7058 Vol 16, Issue 2, 2024